Effects of anti-resorptive agents on trabecular bone score (TBS) in older women.

Details

Ressource 1Download: serval:BIB_EF08F3FD6714.P001 (166.50 [Ko])
State: Public
Version: author
License: Not specified
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Serval ID
serval:BIB_EF08F3FD6714
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effects of anti-resorptive agents on trabecular bone score (TBS) in older women.
Journal
Osteoporosis International
Author(s)
Krieg M.A., Aubry-Rozier B., Hans D., Leslie W.D., Manitoba Bone Density Program
Contributor(s)
Manitoba Bone Density Program
ISSN
1433-2965 (Electronic)
ISSN-L
0937-941X
Publication state
Published
Issued date
2013
Volume
24
Number
3
Pages
1073-1078
Language
english
Notes
Publication types: Journal Article. Publication Status: ppublish. Document Type: Journal Article. Type de document PDF: ORIGINAL ARTICLE.
Abstract
We evaluated the longitudinal effects of anti-resorptive agents (534 treated women vs. 1,150 untreated) on lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). TBS was responsive to treatment in women over age 50. The treatment-related increase in TBS was less than the increase in BMD, which is consistent with bone texture preservation.
INTRODUCTION: In addition to inducing an increase in BMD, anti-resorptive agents also help to preserve bone architecture. TBS, a new gray-level texture measurement, correlates with 3D parameters of bone micro-architecture independent of BMD. Our objective was to evaluate the longitudinal effects of anti-resorptive agents on lumbar spine BMD and TBS.
METHODS: Women (≥50 years), from the BMD program database for the province of Manitoba, Canada, who had not received any anti-resorptive drug prior to their initial dual X-ray absorptiometry (DXA) exam were divided into two groups: untreated, those without any anti-resorptive drug over the course of follow-up, and treated, those with a non-estrogen anti-resorptive drug (86 % bisphosphonates, 10 % raloxifene, and 4 % calcitonin). Lumbar spine TBS was calculated for each lumbar spine DXA examination. Changes in TBS and BMD between baseline and follow-up (mean follow-up 3.7 years), expressed in percentage per year, were compared between the two groups.
RESULTS: A total of 1,150 untreated women and 534 treated women met the inclusion criteria. Only a weak correlation was seen between BMD and TBS in either group. Significant intergroup differences in BMD change and TBS change were observed over the course of follow-up (p < 0.001). Similar mean decreases in BMD and TBS (-0.36 %/year and -0.31 %/year, respectively) were seen for untreated subjects (both p < 0.001). Conversely, treated subjects exhibited a significant mean increase in BMD (+1.86 %/year, p < 0.002) and TBS (+0.20 %/year, p < 0.001).
CONCLUSION: TBS is responsive to treatment with non-estrogen anti-resorptive drug therapy in women over age 50. The treatment-related increase in TBS is less than the increase in BMD, which is consistent with bone texture preservation.
Pubmed
Web of science
Open Access
Yes
Create date
09/01/2013 15:22
Last modification date
01/10/2019 7:20
Usage data